睿知中国医院研究地图
候选清单

正在招募鼻咽癌II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors

ClinicalTrials.gov 上登记的一项鼻咽癌开放试验。牵头方不是本站收录的医院;本站收录的 1 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心中山大学肿瘤防治中心Sun Yat-sen University Cancer Center广州医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT06475300,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 8

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(8 项)收起清单
  1. 18 岁 至 未注明;性别:不限

    登记记录的入选字段

  2. Patients with locally advanced or metastatic non-small cell lung cancer or nasopharyngeal carcinoma confirmed by histopathology and/or cytology;

    入选标准第 5 条

  3. Stage 1 EGFR-sensitive mutant non-small cell lung cancer patients with systemic chemotherapy; Stage 2 patients who had received previous systemic therapy;

    排除标准第 1 条

  4. The toxicity of previous antineoplastic therapy has returned to ≤ grade 1 as defined by NCI-CTCAE v5.0;

    入选标准第 9 条

  5. ECOG 0 or 1;

    入选标准第 8 条

  6. screening period not allowed within 14 days before a blood transfusion, are not allowed to use any cell growth factor, and/or liters of platelet medicine, organ function level must conform to the requirements;

    入选标准第 11 条

    For restructuring or human mouse chimeric antibody on study of humanized anti-platelet antibody has a history of allergies or allergic to BL - B01D1 any supplementary material composition of patients;

    排除标准第 16 条

  7. At least one measurable lesion meeting the RECIST v1.1 definition was required;

    入选标准第 7 条

  8. Before the first delivery within 5 years diagnosed as other malignant tumor;

    排除标准第 7 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:怀孕、哺乳与避孕。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06475300,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Sign the informed consent form voluntarily and follow the protocol requirements;
  2. Any gender;
  3. Age: ≥18 years old;
  4. Expected survival time for 3 months or more;
  5. Patients with locally advanced or metastatic non-small cell lung cancer or nasopharyngeal carcinoma confirmed by histopathology and/or cytology;
  6. Subjects were able to provide 6-10 slides of archived tumor tissue samples or fresh tissue samples of primary or metastatic lesions within 2 years;
  7. At least one measurable lesion meeting the RECIST v1.1 definition was required;
  8. ECOG 0 or 1;
  9. The toxicity of previous antineoplastic therapy has returned to ≤ grade 1 as defined by NCI-CTCAE v5.0;
  10. No serious cardiac dysfunction, left ventricular ejection fraction 50% or higher;
  11. screening period not allowed within 14 days before a blood transfusion, are not allowed to use any cell growth factor, and/or liters of platelet medicine, organ function level must conform to the requirements;
  12. Coagulation function: international normalized ratio (INR) ≤1.5, and activated partial thromboplastin time (APTT) ≤1.5ULN;
  13. The urine protein + 2 or 1000 mg / 24 h or less or less;
  14. For premenopausal women with childbearing potential, a pregnancy test must be performed within 7 days before starting treatment, serum or urine must be negative for pregnancy, and must be non-lactating; All enrolled patients (male or female) were advised to use adequate barrier contraception throughout the treatment cycle and for 6 months after the end of treatment.

排除标准:Exclusion Criteria:

  1. Stage 1 EGFR-sensitive mutant non-small cell lung cancer patients with systemic chemotherapy; Stage 2 patients who had received previous systemic therapy;
  2. In the second stage queue one signed informed consent before gene sequencing report suggests patients such as mutation of ALK fusion;
  3. Anti-tumor therapy such as chemotherapy or biological therapy has been used within 4 weeks or 5 half-lives before the first dose; Mitomycin and nitrosoureas were administered within 6 weeks before the first dose; Fluorouracil class oral drugs, etc.;
  4. Serious heart disease;
  5. Long QT, complete left bundle branch block, III degree atrioventricular block; Serious arrhythmia;
  6. Active autoimmune and inflammatory diseases;
  7. Before the first delivery within 5 years diagnosed as other malignant tumor;
  8. Two antihypertensive drugs poorly controlled hypertension;
  9. Patients with poor glycemic control;
  10. With a history of ILD, current ILD or suspected suffering from such diseases during screening;
  11. Complicated with pulmonary diseases leading to severe respiratory function impairment;
  12. There is a lot of serous cavity effusion, or have a serous cavity effusion and has symptoms, or poorly controlled serous cavity effusion patients;
  13. Imaging studies suggest tumor has violated or package around the chest, neck, pharyngeal large blood vessels;
  14. Unstable thrombotic events requiring therapeutic intervention within 6 months before screening; Infusion-related thrombosis was excluded;
  15. Active central nervous system of patients;
  16. For restructuring or human mouse chimeric antibody on study of humanized anti-platelet antibody has a history of allergies or allergic to BL - B01D1 any supplementary material composition of patients;
  17. Before transplant or allogeneic hematopoietic stem cell transplantation (Allo - HSCT);
  18. Human immunodeficiency virus antibody positive, active tuberculosis, active hepatitis B virus infection or active hepatitis C virus infection;
  19. Active infection requiring systemic therapy;
  20. Subjects with clinically significant bleeding or obvious bleeding tendency within 4 weeks before signing the informed consent;
  21. Had participated in another clinical trial within 4 weeks before the first dose;
  22. Other conditions for trial participation were not considered appropriate by the investigator.

引自 ClinicalTrials.gov, NCT06475300, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06475300,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT06475300